Fenwick & West represented Cepheid (Nasdaq: CPHD), a molecular diagnostics company, in its offering of $345 million aggregate principal amount of 1.25% convertible senior notes due in 2021. The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Morgan Stanley & Co. LLC and Jefferies LLC acted as initial purchasers of the notes.
The Fenwick transaction team included corporate attorneys Douglas Cogen, Jeffrey Vetter, David Michaels, Michael Brown, Andrew Albertson and Morgan Sawchuk.